Breaking News, Trials & Filings

Baxter Flu Vax Shows Promise in Phase III

Baxter and DynPort Vaccine Co. (DVC), achieved positive results from a Phase III study measuring the clinical efficacy for Preflucel, a trivalent seasonal flu vaccine.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Baxter and DynPort Vaccine Co. (DVC), achieved positive results from a Phase III study measuring the clinical efficacy for Preflucel, a trivalent seasonal flu vaccine. The vaccine is made using Baxter’s Vero cell culture platform and does not contain an adjuvant or preservatives. The Phase III study found a 78% overall protection rate against culture-confirmed influenza from flu strains that matched those in the vaccine and a 71% rate of flu prevention from all circulating strains. The study...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters